Assessment of cholesteryl ester transfer protein inhibitors for interaction with proteins involved in the immune response to infection

Journal of Lipid Research

Volumn 51, Issue 5, 2010, Pages 967-974

  Clark, Ronald W ^a   Cunningham, David ^a   Cong, Yang ^a   Subashi, Timothy A ^a   Tkalcevic, George T ^a   Lloyd, David B ^a   Boyd, James G ^a   Chrunyk, Boris A ^a   Karam, George A ^a   Qiu, Xiayang ^a   Wang, Ing Kae ^a   Francone, Omar L ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANACETRAPIB; BACTERICIDAL PERMEABILITY INCREASING PROTEIN; BACTERIUM LIPOPOLYSACCHARIDE; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; CP 532623; LIPOPOLYSACCHARIDE BINDING PROTEIN; TETRAHYDROLIPSTATIN; TORCETRAPIB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BACTERIAL INFECTION; BINDING AFFINITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MOLECULAR SIZE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PURIFICATION; PROTEIN STRUCTURE;

ACUTE-PHASE PROTEINS; ANTIMICROBIAL CATIONIC PEPTIDES; BLOOD PROTEINS; CARRIER PROTEINS; CHOLESTEROL ESTER TRANSFER PROTEINS; HUMANS; INFECTION; LIPOPOLYSACCHARIDES; MEMBRANE GLYCOPROTEINS; PROTEIN BINDING; QUINOLINES; SURFACE PLASMON RESONANCE;

EID: 77951059355     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M002295     Document Type: Article

References (35)

1. Clark, R. W., T. A. Sutfin, R. B. Ruggeri, A. T. Willauer, E. D. Sugarman, G. Magnus-Aryitev, P. G. Cosgrove, T. M. Sand, R. T. Wester, J. A. Williams, et al. 2004. Raising high density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler. Thromb. Vasc. Biol. 24: 490-497.
2. Brousseau, M. E., E. J. Schaefer, M. L. Wolfe, L. Bloeden, A. G. Digenio, R. W. Clark, J. Mancuso, and D. J. Rader. 2004. Effects of a potent inhibitor of cholesteryl ester transfer protein on plasma lipoproteins in patients with low HDL cholesterol. N. Engl. J. Med. 350: 1505-1515.
3. Krishna, R., M. S. Anderson, A. J. Bergman, B. Jin, M. Fallon, J. Cote, K. Rosko, C. Chavez-Eng, R. Lutz, D. M. Bloomfield, et al. 2007. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomized placebo-controlled phase 1 studies. Lancet. 370: 1907-1914. (Pubitemid 350192656)
4. Tall, A. R., L. Yvan-Charvet, and N. Wang. 2007. The failure of torcetrapib. Was it the molecule or the mechanism? Arterioscler. Thromb. Vasc. Biol. 27: 257-260.
5. Barter, P. J., M. Caufield, M. Eriksson, S. M. Grundy, J. J. P. Kastelein, M. Komajda, J. Lopez-Sendon, L. Mosca, J-C. Tardif, D. D. Waters, et al. 2007. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357: 2109-2122.
6. Van Amersfoort, E. S., T. J. C. Van Berkel, and J. Kuiper. 2003. Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. Clin. Microbiol. Rev. 16: 379-414.
7. Dentener, M. A., E. J. U. Von Asmuth, G. J. M. Francot, M. N. Marra, and W. A. Buurman. 1993. Antagonistic effects of lipopolysaccharide binding protein and bactericidal/permeability-increasing protein on lipopolysaccharide-induced cytokine release by mononuclear phagocytes. J. Immunol. 151: 4258-4265.
8. Beamer, L. J., S. F. Carroll, and D. Eisenberg. 1997. Crystal structure of human BPI and two bound phospholipids at 2.4 angstrom resolution. Science. 276: 1861-1864.
9. Beamer, L. J., S. F. Carroll, and D. Eisenberg. 1998. The BPI/LBP family of proteins: a structural analysis of conserved regions. Protein Sci. 7: 906-914.
10. Qiu, X., A. Mistry, M. J. Ammirati, B. A. Chrunyk, R. W. Clark, Y. Cong, J. S. Culp, D. E. Danley, T. B. Freeman, K. F. Geoghegan, et al. 2007. Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules. Nat. Struct. Mol. Biol. 14: 106-113.
11. Hailman, E., J. J. Albers, G. Wolfbauer, A. Tu, and S. D. Wright. 1996. Neutralization and transfer of lipopolysaccharide by phospholipid transfer protein. J. Biol. Chem. 271: 12172-12178.
12. Clark, R. W., R. B. Ruggeri, D. Cunningham, and M. J. Bamberger. 2006. Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action. J. Lipid Res. 47: 537-552.
13. Cunningham, D., W. Lin, L. R. Hoth, D. E. Danley, R. B. Ruggeri, K. F. Geoghegan, B. A. Chrunyk, and J. G. Boyd. 2008. Biophysical and biochemical approach to locating an inhibitor binding site on cholesteryl ester transfer protein. Bioconjug. Chem. 19: 1604-1613.
14. Connolly, D. T., E. S. Krul, D. Heuvelman, and K. C. Glenn. 1996. Inhibition of cholesteryl ester transfer protein by apolipoproteins, lipopolysaccharides, and cholesterol sulfate. Biochim. Biophys. Acta. 1304: 145-160.
15. Masucci-Magoulas, L., P. Moulin, X. C. Jiang, H. Richardson, A. Walsh, J. L. Breslow, and A. Tall. 1995. Decreased cholesteryl ester transfer protein (CETP) mRNA and protein and increased high density lipoprotein following lipopolysaccharide administration in human CETP transgenic mice. J. Clin. Invest. 95: 1587-1594.
16. Lloyd, D. B., P. Bonnette, and J. F. Thompson. 2006. Protein fusions of BPI with CETP retain functions inherent to each. Biochemistry. 45: 12954-12959.
17. Opal, S. M., P. J. Scannon, J. Vincent, M. White, S. F. Carroll, J. E. Palardy, N. A. Parejo, J. P. Pribble, and J. H. Lemke. 1999. Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J. Infect. Dis. 180: 1584-1589.
18. Schultz, H., and J. Weiss. 2007. The bactericidal/permeability-increasing protein (BPI) in infection and inflammatory disease. Clin. Chim. Acta. 384: 12-23.
19. Cazita, P. M., D. F. Barbeiro, A. I. S. Moretti, E. C. R. Quintao, and F. G. Soriano. 2008. Human CETP expression enhances the mouse survival rate in an experimental inflammation model: a novel role for CETP. Shock. 30: 590-595.
20. Brousseau, M. E., M. R. Diffenderfer, J. S. Millar, C. Nortsupha, B. F. Asztalos, F. K. Welty, M. L. Wolfe, M. Rudling, I. Bjorkhem, B. Angelin, et al. 2005. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein species, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler. Thromb. Vasc. Biol. 25: 1057-1064.
21. Millar, J. S., M. E. Brousseau, M. R. Diffenderfer, H. R. Barret, F. K. Welty, A. Faruqi, M. L. Wolfe, C. Nartsupha, A. G. Digenio, J. P. Mancuso, et al. 2006. Effects of cholesteryl ester transfer protein inhibitor torcetrapib on apoprotein B100 metabolism in humans. Arterioscler. Thromb. Vasc. Biol. 26: 1350-1356.
22. Guerin, M., W. Le Goff, E. Duchene, Z. Julia, T. Nguyen, T. Thuren, C. L. Shear, and M. J. Chapman. 2008. Inhibition of CETP by torcetrapib attenuates the atherogenicity of postprandial TG-rich lipoproteins in type IIB hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. 28: 148-154.
23. Wolk, R., D. Chen, R. W. Clark, J. Mancuso, and P. L. Barclay. 2009. Pharmacokinetic, pharmacodynamic and safety profile of a new cholesteryl ester transfer protein inhibitor in healthy human subjects. Clin. Pharmacol. Ther. 86: 430-437.
24. Van Oosten, M., P. C. N. Rensen, E. S. Van Ameersfoort, M. Van Eck, A. Van Dam, J. P. Breve, T. Vogel, A. Panet, T. J. C. Van Berkel, and J. Kuiper. 2001. Apolipoprotein E protects against bacterial lipopolysaccharide-induced lethality. J. Biol. Chem. 276: 8820-8824.
25. Vishnyakova, T. G., A. V. Bocharov, I. N. Baranova, Z. Chen, A. T. Remaley, G. Csako, T. L. Eggerman, and A. P. Patterson. 2003. Binding and internalization of lipopolysaccharide by Cla-1, a human orthologue of rodent scavenger receptor B1. J. Biol. Chem. 278: 22771-22780.
26. Cai, L., A. Ji, F. C. de Beer, L. R. Tannock, and D. R. van der Westhuyzen. 2008. SR-B1 protects against endotoxemia in mice through its roles in glucocorticoid production and hepatic clearance. J. Clin. Invest. 118: 364-375.
27. Khovidhunkit, W., M. Kim, R. A. Memon, J. K. Shigenaga, A. H. Moser, K. R. Feingold, and C. Grunfeld. 2004. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J. Lipid Res. 45: 1169-1196. (Pubitemid 38802622)
28. Vreugdenhil, A. C., A. M. Snoek, C. van 't Veer, J. W. Greve, and W. A. Buurman. 2001. LPS-binding protein circulates in association with apoB-containing lipoproteins and enhances endotoxin-LDL/ VLDL interaction. J. Clin. Invest. 107: 225-234.
29. Kitchens, R. L., and P. A. Thompson. 2003. Impact of sepsis-induced changes in plasma on LPS interactions with monocytes and plasma lipoproteins: roles of soluble CD14, LBP, and acute phase lipoproteins. J. Endotoxin Res. 9: 113-118.
30. Forrest, M. J., D. Bloomfield, R. J. Briscoe, P. N. Brown, A-M. Cumiskey, J. Ehrhart, J. C. Hershey, W. J. Keller, X. Ma, H. E. McPherson, et al. 2008. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Brit. J. Pharmacol. 154: 1465-1473.
31. Hu, X., J. D. Dietz, C. Xia, D. R. Knight, W. T. Loggin, A. H. Smith, H. Yuan, D. A. Perry, and J. Keiser. 2009. Torcetrapib induces aldosterone and cortisol production by an intracellular lar calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition. Endocrinology. 150: 2211-2219.
32. Keidar, S., M. Kaplan, E. Pavlotzky, R. Coleman, T. Havek, S. Hamoud, and M. Aviram. 2004. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development. Circulation. 109: 2213-2220.
33. Leopold, J. A., A. Dam, B. A. Maron, A. W. Scribner, R. Liao, D. E. Handy, R. C. Stanton, B. Pitt, and J. Loscalzo. 2007. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat. Med. 13: 189-197.
34. Brownlee, M. 2005. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 54: 1615-1625. (Pubitemid 40770750)
35. Ceriello, A., R. Assaloni, R. D. Ros, A. Maier, L. Piconi, L. Quagliaro, K. Esposito, and D. Giugliano. 2005. Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress and inflammation in type 2 diabetic patients. Circulation. 111: 2518-2524. (Pubitemid 40696141)